EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

naproxen
(+)-6-methoxy-alpha-methyl-2-naphthalene acetic acid

Supplier Sponsors

Name:(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
CAS Number: 22204-53-1Picture of molecule3D/inchi
ECHA EINECS - REACH Pre-Reg:244-838-7
FDA UNII: 57Y76R9ATQ
XlogP3-AA:3.30 (est)
Molecular Weight:230.26318000
Formula:C14 H14 O3
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:cosmetic agents
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Food Chemicals Codex Listed: No
Soluble in:
 water, 15.9 mg/L @ 25 °C (exp)
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
CosIng:cosmetic data
Cosmetic Uses: skin conditioning
 
Suppliers:
BOC Sciences
For experimental / research use only.
(S)-Naproxen >98%
Odor: characteristic
Use: (S)-Naproxen is a non-selective COX inhibitor.
Glentham Life Sciences
Naproxen, 98%
Glentham Life Sciences
Naproxen, BP grade
 
Safety Information:
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
oral-child TDLo 2250 mg/kg/26W
SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
British Journal of Rheumatology. Vol. 26, Pg. 210, 1987.

oral-dog LD50 > 1000 mg/kg
Yakkyoku. Pharmacy. Vol. 29, Pg. 861, 1978.

unreported-dog LD50 1000 mg/kg
Journal of Clinical Pharmacology. Vol. 15, Pg. 311, 1975.

oral-guinea pig LD50 665 mg/kg
Archives of Toxicology, Supplement. Vol. 7, Pg. 365, 1984.

oral-hamster LD50 1400 mg/kg
Archives of Toxicology, Supplement. Vol. 7, Pg. 365, 1984.

unreported-hamster LD50 4110 mg/kg
Journal of Clinical Pharmacology. Vol. 15, Pg. 311, 1975.

oral-man TDLo 54 mg/kg
KIDNEY, URETER, AND BLADDER: PROTEINURIS GASTROINTESTINAL: NAUSEA OR VOMITING KIDNEY, URETER, AND BLADDER: HEMATURIA
Journal of Toxicology, Clinical Toxicology. Vol. 33, Pg. 173, 1995.

oral-man TDLo 114 mg/kg/10D-
BLOOD: CHANGES IN PLATELET COUNT
Journal of Clinical Pharmacology. Vol. 40, Pg. 124, 2000.

oral-man TDLo 214 mg/kg/30D-
KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION LIVER: OTHER CHANGES LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED"
Postgraduate Medical Journal. Vol. 56, Pg. 368, 1980.

oral-man TDLo 3429 mg/kg/35W
VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION LUNGS, THORAX, OR RESPIRATION: CYANOSIS
Postgraduate Medical Journal. Vol. 68, Pg. 766, 1992.

intraperitoneal-mouse LD50 500 mg/kg
Bollettino Chimico Farmaceutico. Vol. 119, Pg. 600, 1980.

intravenous-mouse LD50 435 mg/kg
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: EXCITEMENT
Journal of Pharmacology and Experimental Therapeutics. Vol. 179, Pg. 114, 1971.

oral-mouse LD50 360 mg/kg
Farmaco, Edizione Scientifica. Vol. 40, Pg. 334, 1985.

unreported-mouse LD50 1234 mg/kg
Journal of Clinical Pharmacology. Vol. 15, Pg. 311, 1975.

intraperitoneal-rat LD50 354 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 9, Pg. 829, 1978.

oral-rat LD50 248 mg/kg
Arzneimittel-Forschung. Drug Research. Vol. 41, Pg. 1265, 1991.

Dermal Toxicity:
subcutaneous-mouse LD50 475 mg/kg
Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 1039, 1972.

subcutaneous-rat LD50 928 mg/kg
LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1272, 1983.

Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
cosmetic agents
Recommendation for naproxen usage levels up to:
 not for fragrance use.
 
Recommendation for naproxen flavor usage levels up to:
 not for flavor use.
 
Safety References:
EPI System: View
ClinicalTrials.gov:search
Daily Med:search
Chemical Carcinogenesis Research Information System:Search
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :156391
National Institute of Allergy and Infectious Diseases:Data
(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
Chemidplus:0022204531
RTECS:UF5275000 for cas# 22204-53-1
 
References:
 (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
NIST Chemistry WebBook:Search Inchi
Pubchem (cid):156391
Pubchem (sid):134995706
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
CHEBI:View
CHEMBL:View
KEGG (GenomeNet):C01517
HMDB (The Human Metabolome Database):HMDB01923
FooDB:FDB022741
Export Tariff Code:2918.90.4000
MedlinePlusSupp:View
ChemSpider:View
Wikipedia:View
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 not found in nature
 
Synonyms:
 acusprain
 anexopen
 clinosyn
 danaprox
 flexipen
 genoxen
 laraflex
(+)-(S)-6-methoxy-a-methyl-2-naphthaleneacetic acid
(+)-6-methoxy-alpha-methyl-2-naphthalene acetic acid
(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
 nalyxan
 pronaxen
 rheumaflex
 soproxen
 traumox
 veradol
 xenar
 
 
Notes:
Naproxen (INN) is a non-steroidal anti-inflammatory drug (NSAID) commonly used for the reduction of mild to moderate pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, injury (like fractures), menstrual cramps, tendonitis, bursitis, and the treatment of primary dysmenorrhea. Naproxen and naproxen sodium are marketed under various trade names including: Aleve, Anaprox, Naprogesic, Naprosyn, Naprelan; Naproxen is a non-steroidal anti-inflammatory drug (NSAID) commonly used for the reduction of mild to moderate pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, injury (like fractures), menstrual cramps, tendonitis, bursitis, and the treatment of primary dysmenorrhea. Naproxen and naproxen sodium are marketed under various trade names including: Aleve, Anaprox, Naprogesic, Naprosyn, Naprelan. Naproxen was first marketed as the prescription drug Naprosyn in 1976 and naproxen sodium was first marketed under the trade name Anaprox in 1980. It remains a prescription-only drug in much of the world. The U.S. Food and Drug Administration (FDA) approved the use of naproxen sodium as an over-the-counter (OTC) drug in 1991, where OTC preparations are sold under the trade name Aleve. In Australia, small packets of lower-strength preparations of naproxen sodium are Schedule 2 Pharmacy Medicines; Naproxen is a member of the 2-arylpropionic acid (profen) family of NSAIDs. It is an odorless, white to off-white crystalline substance. It is lipid-soluble, practically insoluble in water with a low pH (below pH 4), while freely soluble in water at 6 pH and above. Naproxen has a melting point of 153 degree centigrade. [HMDB]
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy